Next Generation Cancer Detection and Active Surveillance Testing
for Prostate Cancer and Breast Cancer

OTraces has developed a blood-based disease testing platform that uses math- and physics-based noise suppression techniques never before employed in human disease testing, and has thereby achieved 90%+ accuracy in the detection of cancer tumors as measured by predictive power. This is significantly higher than the IVD industry average and all known competing technologies including DNA-based liquid biopsy.

This technology has enabled OTraces to become the first and only blood test modality that can access the diagnostic content of the tumor microenvironment (TME) — the cellular structures and fluids that surround the tumor that recent research has indicated is a vast storehouse of diagnostic information that may far exceed tumor markers or DNA alone. In effect, the TME is a multi-dimensional and multiphasic information source whose content changes dynamically as the cancer progresses, starting with early tumor formation.

OTraces uses FDA-compliant archival software and secure cloud-based transmission so that all data is collected and securely stored in a U.S. based server platform.

OTraces has averaged predictive power1 of 90%-plus in over 2,000 tests for detecting multiple cancer tumor types, including validation trials for prostate cancer now being conducted at the Johns Hopkins University Medical Center and for breast cancer now underway at the Gertsen Institute in Moscow.

OTraces blood-based disease detection system harnesses math-based measurement science, not unlike those methods used in other fields like space communications to resolve signal complexity, to create proprietary software and algorithms that reduce biologic noise. OTraces has modified and refined these techniques as necessary to address the unique challenges of cancer detection with very encouraging results.

The accuracy-enhancement algorithms that drives the company’s cancer screening tests now in development is expected to attract significant industry interest from other companies and labs seeking to optimize existing test modalities (the OTraces method is biomarker agnostic) through cloud-based collaborations with OTraces on either a fee-for-service or revenue-share basis.

The advantages of using the TME approach to cancer blood testing include the following
. Determination of whether cancer is present or not.
. Differentiation between aggressive and quiescent tumors or pre-tumor mutant DNA
. Determination of cancer tumor stage.

1Predictive power is the average of sensitivity and specificity.

-Presentation at the RESI / J.P. Morgan Healthcare 2018
-RESI 2018 Session Poster Presentation.
-Beyond Liquid Biopsy-OTraces White Paper


Company/Investor Inquiries:
Keith Lingenfelter
phone: +01-301-529-3824
email: keith.lingenfelter@otraces.com

Contact-Media Inquiries:
Nancy Rose Senich
phone: +01-202-262-6996 cell/txt
email: nancy@rose4results.com